Skip to main content

Advertisement

Table 1 Baseline characteristics of the study population, in median (IQR)

From: Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease

Variable Units Median 25th Pctl 75th Pctl n
BMI kg/m2 30.2 27.9 34.1 39
Age years 64.0 58.0 68.0 39
Weight kg 93.0 85.0 108.0 39
HbA1ca mmol/mol 47 (6)    39
Fasting glucose mmol/l 5.3 5.0 6.2 39
Fasting glucagona pmol/l 5.3 (3.5)    
Fasting C-peptide pmol/l 1474 1006 1978 39
Fasting insulin pmol/l 110 67 178 38
Fasting NEFA mmol/l 0.392 0.298 0.455 39
AUCglucose mmol/l × 120min 821.3 750.5 915.5 39
AUCinsulin pmol/l × 120min 33,173 25,350 45,625 38
AUCISR pmol/kg 969.5 811.1 1263.6 38
AUCNEFA mmol/l × 120min 28.9 22.5 36.1 39
HOMA-IR   4.43 2.24 6.93 38
ISIComposite l2/mg/microU 3.2 2.03 4.62 38
B-total   2.54 1.61 3.2 38
MCRikg l/kg/min 0.029 0.023 0.036 37
MCRitotal l/min 2.548 2.219 3.164 37
DI   8.06 5.71 12.91 37
IDRbasal pmol/kg/min 3.09 1.94 4.02 37
HEXi   0.30 0.22 0.36 37
Pre-study ADTb n (%)     
Diet and lifestyle intervention 24 (62)     
Metformin 15 (38)     
Sulfonylurea 1 (3)     
  1. aMean (SD)
  2. bAnti diabetic treatment